Silence Therapeutics plc

# Signal Note: Redmile Initiates Silence Therapeutics Position Redmile's $13.2M entry into Silence (2.16M shares, ~5.5% stake) signals confidence in the RNAi platform ahead of near-term catalysts, likely including LPCN 1144 Phase 2b data for NASH (expected late 2024/early 2025) and potential partnerships. Green's healthcare crossover focus suggests conviction in the commercial pathway for a non-alcoholic fatty liver disease asset, where RNAi has demonstrated clinical proof-of-concept but faces competition from GLP-1 programs. Position sizing and timing indicate tactical entry ahead of data readout rather than near-term liquidation risk.